Fig. 5: Inhalation of mnbTSLP-iLNPBUD5 mitigates airway damage in established acute asthma models. | Nature Communications

Fig. 5: Inhalation of mnbTSLP-iLNPBUD5 mitigates airway damage in established acute asthma models.

From: Budesonide-incorporated inhalable lipid nanoparticles for antiTSLP nanobody mRNA delivery to treat steroid-resistant asthma

Fig. 5

a Schematic illustration of the OVA-induced asthma model and treatment regimen in BALB/c mice. b Histological analysis of lung sections from mice subjected to the indicated treatments. Lung tissue was processed and stained using H&E to assess overall tissue morphology, PAS staining to evaluate mucus production, and Masson staining to examine collagen deposition. Black arrows indicate inflammatory cells, mucus, and collagen, respectively. Scale bars, 200 μm (Above). Scale bars, 50 μm (Below). c–f, Quantification analysis of histological staining in lung sections. (c) Airway wall thickness, (d) inflammatory cell infiltration, (e) mucus production area, and (f) collagen content were quantified using ImageJ software. Results are presented as mean ± s.d, n = 5 biologically independent mice per group (c–f). Significant differences were assessed using a one-way ANOVA with Tukey’s multiple comparisons test (c–f). Source data are provided as a Source Data file.

Back to article page